Author:
Capelli Chiara,Cuofano Carolina,Pavoni Chiara,Frigerio Simona,Lisini Daniela,Nava Sara,Quaroni Michele,Colombo Valentina,Galli Francesco,Bezukladova Svetlana,Panina-Bordignon Paola,Gaipa Giuseppe,Comoli Patrizia,Cossu Giulio,Martino Gianvito,Biondi Andrea,Introna Martino,Golay Josée
Abstract
Advanced Therapy Medicinal Products (ATMPs) based on somatic cells expanded in vitro, with or without genetic modification, is a rapidly growing area of drug development, even more so following the marketing approval of several such products. ATMPs are produced according to Good Manufacturing Practice (GMP) in authorized laboratories. Potency assays are a fundamental aspect of the quality control of the end cell products and ideally could become useful biomarkers of efficacy in vivo. Here we summarize the state of the art with regard to potency assays used for the assessment of the quality of the major ATMPs used clinic settings. We also review the data available on biomarkers that may substitute more complex functional potency tests and predict the efficacy in vivo of these cell-based drugs.
Funder
Fondazione per la Ricerca Biomedica
Subject
Immunology,Immunology and Allergy
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献